Last updated: June 17, 2026
Litigation summary and analysis: Boehringer Ingelheim Pharmaceuticals Inc. v. Ridhisidhi PLLC, 1:26-cv-00372
Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) sued Ridhisidhi PLLC in the District of Delaware in a Hatch-Waxman-style patent case filed under No. 1:26-cv-00372. The docket is new and the available public record in this workspace does not include the asserted patents, claims, ANDA/BLA details, filing date timeline, or infringement and noninfringement/invalidity positions. No litigation-specific analysis can be produced without those case merits inputs.
What is the docket entry status for Boehringer Ingelheim v. Ridhisidhi PLLC (1:26-cv-00372)?
A complete litigation summary requires at minimum: complaint filing date, patents asserted (numbers and expiration dates), asserted dosage forms/indications, the FDA application referenced (ANDA number or other), and the presence of any Paragraph IV certifications and counterclaims.
What patents does Boehringer Ingelheim assert in 1:26-cv-00372?
Litigation analysis depends on the patent estate being challenged:
- patent numbers and titles
- whether the theory is composition, method-of-use, formulation, or device/delivery
- claim construction posture (if any orders exist)
- infringement allegations keyed to product labels or ANDA specs
Those specifics are not present in the provided material.
What Orange Book and FDA application is at issue in 1:26-cv-00372?
A Hatch-Waxman Paragraph IV case typically maps to:
- Orange Book listing(s) for the reference listed drug
- the ANDA filing number
- the certification(s) (Paragraph IV vs. other)
- timing triggers for any generic entry risk
This mapping cannot be stated from the information available here.
How strong is Boehringer Ingelheim’s patent estate in this case?
A strength assessment requires:
- each asserted patent’s remaining term
- prosecution history and known validity challenges
- whether any asserted claims have survived prior litigation
- whether the asserted claims cover the specific generic manufacturing method or formulation
No asserted-patent list or claim set is available here.
What defenses and counterclaims does Ridhisidhi PLLC raise (invalidity, noninfringement, unenforceability)?
Merits analysis requires the actual defenses pleaded, including:
- obviousness/anticipation bases and references
- priority dates and claim construction disputes
- 35 U.S.C. § 112 (written description/enablement/indefiniteness) arguments
- inequitable conduct or other enforceability challenges
Those details are not available in the provided material.
Has the court issued any rulings, scheduling orders, or claim construction in 1:26-cv-00372?
For litigation tracking and risk scoring, the key inputs are:
- complaint service date and response deadlines
- Markman/claim construction order
- preliminary injunction motion activity (if any)
- trial scheduling and dispositive motion deadlines
The provided material does not include any docket rulings.
What is the likely procedural posture in 2026 for 1:26-cv-00372?
In the absence of docket events, a procedural posture cannot be anchored to facts. A credible timeline requires docket dates for answers, amended pleadings, expert disclosures, and motions.
How does this case affect Boehringer Ingelheim’s exclusivity and generic entry timelines?
A generic entry impact analysis requires:
- which patents are asserted relative to FDA listing status
- whether any patents are near-expiration
- whether there is an automatic 30-month stay triggered by a Paragraph IV ANDA
No Orange Book listing or certification detail is present here.
What settlement, consent judgment, or licensing outcomes are indicated for 1:26-cv-00372?
Settlement value and expected launch dates depend on:
- any stipulations of dismissal
- license agreements or covenant not to sue
- agreed-upon launch triggers or design-around commitments
No settlement terms or consent activity are available here.
Which companies are in the competitive landscape for the same drug product at issue?
Competitive assessment requires identifying:
- the reference listed drug (RLD)
- its label and dosage forms
- other ANDA filers and generic launch history in the same Orange Book matrix
The underlying product is not identified in the provided material.
Key Takeaways
- The docket number (1:26-cv-00372) and parties are identified, but the asserted-patent set, FDA application details, and docket events are not provided in the available record here.
- Without asserted patents, claim theories, and procedural rulings, no litigation-specific infringement/validity/strategy analysis is supportable.
FAQs
- What is the fastest way to determine which patents are at issue in 1:26-cv-00372?
- How do Paragraph IV certifications typically drive timelines in Hatch-Waxman cases like 1:26-cv-00372?
- What docket events most influence generic entry risk (claim construction, injunction rulings, trial scheduling)?
- How is patent strength measured in district court cases: term remaining, claim coverage, and prior litigation outcomes?
- What settlement terms commonly appear in pharmaceutical patent cases involving ANDA filers?
References
- United States District Court for the District of Delaware. Boehringer Ingelheim Pharmaceuticals Inc. v. Ridhisidhi PLLC, No. 1:26-cv-00372 (case docket).
